Zietek Z, Iwan-Zietek I, Kotschy M, Tyloch F
Katedry i Kliniki Urologii, Katedry i Zakładu Patofizjologii Akademii Medycznej, Bydgoszczy.
Pol Tyg Lek. 1996 Feb;51(6-9):86-8.
In the blood of 20 patients with prostatic carcinoma the level of alpha 2-antiplasmin and plasminogen were examined. The control group consisted of 20 patients with benign prostatic hyperplasia. The low activity of alpha 2-antiplasmin in the blood of the patients with prostatic carcinoma was observed. The level of plasminogen was similar in both groups and it was in the low part of laboratory normal range. We concluded that the low levels of plasminogen and alpha 2-antiplasmin were a result of their consumption during activation of fibrinolysis process. The measurement of the alpha 2-antiplasmin and plasminogen can be useful to predict a risk of bleeding complications in the patients with prostatic carcinoma and benign prostatic hyperplasia.
检测了20例前列腺癌患者血液中α2 -抗纤溶酶和纤溶酶原的水平。对照组由20例良性前列腺增生患者组成。观察到前列腺癌患者血液中α2 -抗纤溶酶活性较低。两组患者的纤溶酶原水平相似，且处于实验室正常范围的下限。我们得出结论，纤溶酶原和α2 -抗纤溶酶水平较低是它们在纤溶过程激活期间被消耗的结果。检测α2 -抗纤溶酶和纤溶酶原有助于预测前列腺癌和良性前列腺增生患者出血并发症的风险。
